article thumbnail

‘In vivo’ cell therapy: expanding beyond CAR-T

Bio Pharma Dive

At least five startups have emerged with new ways to genetically modify immune cells within the body, an approach that, if successful, could widen the field of CAR-T treatment.

In-Vivo 359
article thumbnail

FDA clears Intellia to start US tests of ‘in vivo’ gene editing drug

Bio Pharma Dive

The announcement, which follows recent regulatory setbacks for some of Intellia’s peers, is a “big win” for the gene editing field, according to one analyst.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Virtual workshop - Unveiling the Potency-Efficacy Connection: Integrating Functional Assay Readouts for In Vivo Insights

pharmaphorum

Virtual workshop - Unveiling the Potency-Efficacy Connection: Integrating Functional Assay Readouts for In Vivo Insights Mike.Hammerton Fri, 05/26/2023 - 14:00 Bookmark this

In-Vivo 52
article thumbnail

Ensoma buys a startup to advance ‘in vivo’ cell therapy work

Bio Pharma Dive

The Takeda-backed biotech revealed it’s raised $85 million in new funding alongside announcing the acquisition of gene editing startup Twelve Bio.

In-Vivo 317
article thumbnail

FDA clears in vivo gene editing therapy for trials in US

Drug Discovery World

The post FDA clears in vivo gene editing therapy for trials in US appeared first on Drug Discovery World (DDW). Intellia’s multi-national Phase I/II study is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of NTLA-2002 in adults with Type I or Type II HAE.

In-Vivo 52
article thumbnail

Intellia, Regeneron ace first trial with ‘in vivo’ CRISPR drug

pharmaphorum

So far, human trial data for gene-editing drugs have been generated for ex vivo therapies, meaning the CRISPR technology is used to modify cells outside the body, which are then reinfused into the patient. — Eric Topol (@EricTopol) June 26, 2021. — Eric Topol (@EricTopol) June 26, 2021.

In-Vivo 105
article thumbnail

A startup launches with plans to open up a gene and cell therapy bottleneck

Bio Pharma Dive

The pipeline of CAR-T therapies and ex vivo gene therapies has swelled in recent years, but manufacturing hasn’t been able to keep up with demand.

Gene 306